Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma

.
Source: British Journal of Neurosurgery - Category: Neurosurgery Authors: Source Type: research

Related Links:

The interaction of programmed death-1 protein (PD-1) and programmed death-1 ligand (PD-L1) produces immunosuppressive activity, protecting tumor cells from anti-tumor immunity and possibly releasing soluble PD...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Primary Central Nervous System Lymphoma (PCNSL) may manifest initially in the eye (termed vitreoretinal lymphoma or VRL) or in non-ocular CNS compartments, or in both. The nature of the onset of PCNSL implies two clinical specialists – ophthalmologists and neuro-oncologists – independently may assess the primary presentation of this rare malignancy. Clinically relevant perspectives on expectations of PCNSL manifestation in both ocular and non-ocular CNS compartments would help inform management practices in each specialty, w hich should impact clinical outcomes.
Source: Survey of Ophthalmology - Category: Opthalmology Authors: Tags: Major review Source Type: research
This report describes the clinical presentation and histopathologic findings in 2 patients who initially received a diagnosis of primary CNS vasculitis, but did not show long-term response to treatment. In both cases, a second biopsy was performed, and the final diagnosis was primary CNS lymphoma (PCNSL). Summary Analyzing diagnostically challenging cases can increase recognition of PCNSL and improve outcomes in this rare condition.
Source: Neurology Clinical Practice - Category: Neurology Authors: Tags: Vasculitis, Primary brain tumor Review Source Type: research
Primary central nervous system (CNS) marginal zone B ‐cell lymphoma (MZBCL) arising from the dural meninges is a rare but indolent disease. This malignancy can present in various ways, hence making it difficult to diagnose. Biopsy results dictate an appropriate treatment plan, which commonly consists of a combination of surgical resection, whole bra in radiotherapy and systemic therapy. AbstractPrimary central nervous system (CNS) marginal zone B ‐cell lymphoma (MZBCL) arising from the dural meninges is a rare but indolent disease. This malignancy can present in various ways, hence making it difficult to diagnose. Biop...
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
Condition:   Primary Central Nervous System Lymphoma (PCNSL) Intervention:   Other: Tumor samples and MRI Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionWe are evaluating the effectiveness of maintenance immunotherapy in PCNSL in a prospective multicenter randomized clinical trial.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
ConclusionThe Taipei Score is a simple model that discriminates PFS and OS for PCNSL patients. The score may offer disease risk stratification and facilitate clinical decision ‐making.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product ...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
AbstractManagement of lesions involving Meckel's cave can represent a challenge for neurosurgeons, because of the deep-seated location and the surrounding complex neurovascular structures. Very small lesions arising from MC are generally asymptomatic and radiological follow-up with head MRI and PET-CT is sufficient to control these lesions. In rare cases, the rapid increase in the size of lesions and the alteration of the neurologic status make early histological characterization mandatory in the plethora of lesions arising from Meckel's cave; a very small percentage is represented by central nervous system lymphomas. Prim...
Source: Acta Neurologica Belgica - Category: Neurology Source Type: research
Primary CNS lymphoma (PCNSL) is a variant of NHL, involving the brain, leptomeninges, spinal cord, and/or the eyes without any evidence of systemic disease. Optimal therapy in PCNSL is yet to be determined. High dose methotrexate (HD-MTx) forms the mainstay of treatment. Consolidation strategies include radiation, non-myeloablative chemotherapy or myeloablative chemotherapy followed by stem cell rescue (ASCT). Thiotepa-based conditioning is preferred for ASCT based on evidence of superiority over BEAM conditioning.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 352 Source Type: research
More News: Brain | Lymphoma | Neurology | Neurosurgery | Primary CNS Lymphoma | UK Health